Phase 1 Endometrial Cancer trials recruiting now

All Endometrial Cancer trials, every phase

Other phases for Endometrial Cancer

Phase 1 Endometrial Cancer trials

• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
  NCT07189871 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Beta-only IL-2 ImmunoTherapY Study
  NCT05086692 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 27 locations
• A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
  NCT07623369 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 9 locations
• A Phase 1 Study of LNCB74 in Advanced Solid Tumors
  NCT06774963 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
  NCT07109726 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 164 locations
• A Study of BL0175 Injection in Postmenopausal Female Adults With HR-positive, Locally Advanced or Metastatic Cancer
  NCT06738966 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
  NCT06999187 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
  NCT05377996 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• A Study of GV20-0251 in Advanced or Refractory Solid Tumors
  NCT07106827 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of MGC026 in Participants With Advanced Solid Tumors
  NCT06242470 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 36 locations
• A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
  NCT06547840 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 7 locations
• A Study of MT-4561 in Patients With Various Advanced Solid Tumors
  NCT06943521 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
  NCT07383506 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
  NCT06395519 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
  NCT05208762 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
  NCT07227168 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  NCT04104776 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 160 locations
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
  NCT07612891 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
  NCT07610798 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
  NCT07371663 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
  NCT06239194 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
  NCT07262619 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
  NCT05983432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 117 locations
• ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
  NCT05542407 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Female · 1 location
• Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
  NCT06293898 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
  NCT05856981 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
  NCT06218914 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
  NCT05579366 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 66 locations
• SL-28 for Advanced Solid Tumours
  NCT07341737 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
  NCT05799274 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
  NCT07444814 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Study of AVZO-021 in Patients With Advanced Solid Tumors
  NCT05867251 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
  NCT06974110 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
  NCT07524322 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
  NCT04969315 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  NCT04585750 · Phase: Phase 1, Phase 2 · Ages: 12 Years and older · Sex: All (male and female) · 154 locations

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.